FDA approves expanded monotherapy label for Merck’s KEYTRUDA® (pembrolizumab)
Merck announced the FDA has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for first-line treatment of patients with stage III non-small cell lung cancer who are not candidates for surgical resection. April 12, 2019